timothy sykes logo
Co-Diagnostics Surges After Market Expansion News Thumbnail
ADD US ONG Google News

Co-Diagnostics Surges After Market Expansion News

JACK KELLOGG•UPDATED MAR. 11, 2026, 9:18 AM ET
Reviewed by Ellis Hobbs Fact-checked by Matt Monaco

Co-Diagnostics Inc.’s stocks have been trading down by -13.64 percent amid rising investor concerns about market competition.

Candlestick Chart

Live Update At 09:17:54 EDT: On Wednesday, March 11, 2026 Co-Diagnostics Inc. stock [OTC: CODX] is trending down by -13.64%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Co-Diagnostics, Inc. has managed to capture the market’s attention with its recent quarter earnings. For the quarter ending Sep 30, 2025, the company reported a total revenue of $145K, whereas a year prior, revenue stood at $3.9M. Such a drastic decline in revenue reflects an 18% decrease year on year. The significant drop can be attributed to reduced demand for its Logix Smart COVID-19 test as pandemic concerns wane globally. Interestingly though, the company has been pursuing avenues beyond the COVID-19 test kits, focusing on expanding its product portfolio.

The operating income for the quarter was reported at a loss of $7M, marking a stark contrast to its total revenue figures. In broader financial terms, Co-Diagnostics’ debt-to-equity ratio stands at 0.04, illustrating a firm commitment to sustaining minimum leverage. What’s noteworthy is their current assets, which exceed $14M. It fortifies the company’s financial position, providing a cushion amidst the earnings downturn.

Expansion Moves Elevate Market Sentiment

The market’s response to Co-Diagnostics’ latest expansion attempt has been very positive. As strategic partnerships unfold, a brighter business landscape seems on the horizon. The recent partnership in Europe is said to fortify their market presence, enabling higher penetration of their cutting-edge molecular diagnostics technology. This strategic move not only broadens their geographical influence but reinforces their brand image as a leader in diagnostics solutions.

More Breaking News

Such partnerships bode well for future revenue projections and earnings potential, despite current setbacks in financial reports. Market analysts remain optimistic, with several forecasting marked improvements in quarterly sales figures for the quarters ahead. The long-term prospects of a resilient market presence, backed by patented technology and expert collaborations, also enhance investor confidence, smoothing stock volatility.

Market Dynamics and Trends

Stock price movement revealed a significant spike as soon as trading commenced today. It marked an ascending trajectory that continued throughout the session. Opening at $3.8 per share and reaching a high of $4.4 marked a whopping 25% appreciation. This considerable spike can be attributed to the anticipated benefits from the recent European expansion deal.

The company’s recent effort throws light upon its strategic goal to expand its geographic footprint and diversify its product applications beyond traditional offerings. Such a robust surge directly reflects market optimism, signifying strong investor confidence in Co-Diagnostics’ ability to meet the new demands efficiently and effectively. Given those market dynamics, stakeholders seem keen to seize this opportunity, fuelling further short-term price momentum.

Conclusion

As Co-Diagnostics exhibits remarkable capability and ambition to harness new opportunities, the shareholder landscape grows increasingly vibrant. The firm’s unwavering commitment to technological advancements and strategic expansion fuels market optimism amid a broader diagnostic market recovery.

By prioritizing collaborative ventures and staying in sync with evolving healthcare trends, Co-Diagnostics might very well surpass its revenue slump in no time. As traders rally and enterprise initiatives blossom, the promising bounds of Co-Diagnostics’ financial journey remain open to exploration. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This mindset encourages traders to stay mindful and prudent amidst market fluctuations. Withstanding these fluctuations and harnessing growth potential, the company appears well-poised to prosper in the competitive diagnostics field.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading [TICKER]

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”